To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.

Gregory L. Beatty, MD, PhD
Tumor-associated immune cells called macrophages are a key component of the tumor microenvironment and often portend a poor prognosis. Macrophages are critical regulators of tumor angiogenesis and metastasis. Interestingly, the function of macrophages is dependent on their surrounding microenvironment such that under certain conditions, macrophages can actually become tumor-suppressive. The central hypothesis of Dr. Beatty’s work is that macrophages are an important yet pliable factor in tumor behavior, which can be therapeutically targeted and instructed to attack tumors and inhibit tumor growth.
Dr. Beatty [Nadia’s Gift Foundation Innovator] will evaluate strategies to engineer macrophages to attack tumors and to resist signals produced within tumors that ordinarily prime macrophages with tumor-promoting properties. He aims to combine these macrophage-directed approaches with standard chemotherapy. The priority is to develop the necessary data to facilitate the rapid translation of this strategic approach to the clinic for treatment of patients with pancreatic cancer and other malignancies.
Project Title: "Targeting macrophages for cancer therapy"
Institution: University of Pennsylvania
Sponsor(s) / Mentor(s): n/a
Cancer Type: All cancers
Research Area: Immunotherapy


